Sökning: WFRF:(Borg Philip) >
Value of Tumor Grow...
Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET) : The GREPONET Study
-
- Lamarca, Angela (författare)
- Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
-
- Crona, Joakim (författare)
- Uppsala universitet,Endokrinkirurgi,Endokrin tumörbiologi
-
- Ronot, Maxime (författare)
- Department of Radiology, Beaujon University Hospital, Clichy, France
-
visa fler...
-
- Opalinska, Marta (författare)
- Nuclear Medicine Unit, Department of Endocrinology, University Hospital, Krakow, Poland
-
- Lopez Lopez, Carlos (författare)
- Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain
-
- Pezzutti, Daniela (författare)
- Department of Radiology, Israelita Albert Einstein Hospital, Sao Paulo, Brazil
-
- Najran, Pavan (författare)
- Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom
-
- Carvhalo, Luciana (författare)
- Department of Medical Oncology, Sirio‐Libanes Hospital, Sao Paulo, Brazil
-
- Franca Bezerra, Regis Otaviano (författare)
- Department of Radiology, Sirio‐Libanes Hospital, Sao Paulo, Brazil ; São Paulo Cancer Institute Octavio Frias de Oliveira, Sao Paulo, Brazil
-
- Borg, Philip (författare)
- Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom
-
- Vietti Violi, Naik (författare)
- Department of Radiology, CHUV University Hospital, Lausanne, Switzerland
-
- Vidal Trueba, Hector (författare)
- Department of Radiology, Hospital Universitario Marques de Valdecilla, Santander, Spain
-
- de Mestier, Louis (författare)
- Department of Gastroenterology, Beaujon University Hospital, Clichy, France
-
- Schaefer, Niklaus (författare)
- Department of Medical Oncology, CHUV University Hospital, Lausanne, Switzerland
-
- Sundin, Anders, 1954- (författare)
- Uppsala universitet,Radiologi
-
- Costa, Frederico (författare)
- Department of Medical Oncology, Sirio‐Libanes Hospital, Sao Paulo, Brazil
-
- Pavel, Marianne (författare)
- Department of Medicine 1, Division of Endocrinology, Friedrich‐Alexander University Erlangen‐Nürnberg, Erlangen, Germany
-
- Dromain, Clarisse (författare)
- Department of Radiology, CHUV University Hospital, Lausanne, Switzerland
-
visa färre...
-
(creator_code:org_t)
- 2019-03-25
- 2019
- Engelska.
-
Ingår i: The Oncologist. - : Oxford University Press (OUP). - 1083-7159 .- 1549-490X. ; 24:11, s. E1082-E1090
- Relaterad länk:
-
https://theoncologis...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- INTRODUCTION: Tumor growth rate (TGR; percent size change per month [%/m]) is postulated to be an early radiological biomarker to overcome limitations of RECIST. This study aimed to assess the impact of TGR in neuroendocrine tumors (NETs) and potential clinical and therapeutic applications.MATERIALS AND METHODS: Patients (pts) with advanced grade (G) 1/2 NETs from the pancreas or small bowel initiating systemic treatment (ST) or watch and wait (WW) were eligible. Baseline and follow-up scans were retrospectively reviewed to calculate TGR at pretreatment (TGR0), first follow-up (TGRfirst), and 3(±1) months of study entry (TGR3m).RESULTS: Out of 905 pts screened, 222 were eligible. Best TGRfirst (222 pts) cutoff was 0.8 (area under the curve, 0.74). When applied to TGR3m (103 pts), pts with TGR3m <0.8 (66.9%) versus TGR3m ≥ 0.8 (33.1%) had longer median progression-free survival (PFS; 26.3 m; 95% confidence interval [CI] 19.5-32.4 vs. 9.3 m; 95% CI, 6.1-22.9) and lower progression rate at 12 months (7.3% vs. 56.8%; p = .001). WW (vs. ST) and TGR3m ≥ 0.8 (hazard ratio [HR], 3.75; 95% CI, 2.21-6.34; p < .001) were retained as factors associated with a shorter PFS in multivariable Cox regression. TGR3m (HR, 3.62; 95% CI, 1.97-6.64; p < .001) was also an independent factor related to shorter PFS when analysis was limited to pts with stable disease (81 pts). Out of the 60 pts with TGR0 data available, 60% of pts had TGR0 < 4%/month. TGR0 ≥ 4 %/month (HR, 2.22; 95% CI, 1.15-4.31; p = .018) was also an independent factor related to shorter PFS.CONCLUSION: TGR is an early radiological biomarker able to predict PFS and to identify patients with advanced NETs who may require closer radiological follow-up.IMPLICATIONS FOR PRACTICE: Tumor growth rate at 3 months (TGR3m) is an early radiological biomarker able to predict progression-free survival and to identify patients with advanced neuroendocrine tumors who may require closer radiological follow-up. It is feasible to calculate TGR3m in clinical practice and it could be a useful tool for guiding patient management. This biomarker could also be implemented in future clinical trials to assess response to therapy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- NET
- Neuroendocrine tumor
- Progression‐free survival
- TGR
- Tumor growth rate
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lamarca, Angela
-
Crona, Joakim
-
Ronot, Maxime
-
Opalinska, Marta
-
Lopez Lopez, Car ...
-
Pezzutti, Daniel ...
-
visa fler...
-
Najran, Pavan
-
Carvhalo, Lucian ...
-
Franca Bezerra, ...
-
Borg, Philip
-
Vietti Violi, Na ...
-
Vidal Trueba, He ...
-
de Mestier, Loui ...
-
Schaefer, Niklau ...
-
Sundin, Anders, ...
-
Costa, Frederico
-
Pavel, Marianne
-
Dromain, Clariss ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
The Oncologist
- Av lärosätet
-
Uppsala universitet